| Literature DB >> 26386022 |
Othman Al-Sawaf1, Tim Clarner2, Athanassios Fragoulis3, Yuet Wai Kan4, Thomas Pufe5, Konrad Streetz6, Christoph Jan Wruck1.
Abstract
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a major regulator of oxidative stress defence in the human body. As Nrf2 regulates the expression of a large battery of cytoprotective genes, it plays a crucial role in the prevention of degenerative disease in multiple organs. Thus it has been the focus of research as a pharmacological target that could be used for prevention and treatment of chronic diseases such as multiple sclerosis, chronic kidney disease or cardiovascular diseases. The present review summarizes promising findings from basic research and shows which Nrf2-targeting therapies are currently being investigated in clinical trials and which agents have already entered clinical practice.Entities:
Keywords: Nrf2; cardiovascular disease; chronic kidney disease; clinical trials; multiple sclerosis; oxidative stress
Mesh:
Substances:
Year: 2015 PMID: 26386022 DOI: 10.1042/CS20150436
Source DB: PubMed Journal: Clin Sci (Lond) ISSN: 0143-5221 Impact factor: 6.124